Sichuan Baili Pharmaceutical Co., Ltd.
Clinical trials sponsored by Sichuan Baili Pharmaceutical Co., Ltd., explained in plain language.
-
New hope for aggressive lung cancer: major trial launches
Disease control Not yet recruitingThis large Phase 3 trial will compare a new experimental drug, BL-B01D1, combined with an immunotherapy (tislelizumab) against the current standard platinum-based chemotherapy combined with the same immunotherapy. It aims to see if the new combination helps people with extensive-…
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
First human test for new hope against tough blood cancers
Disease control Not yet recruitingThis is a first-in-human study to test the safety and initial effects of a new drug called BL-M24D1. It is for adults with advanced multiple myeloma or other blood cancers that have come back or stopped responding to standard treatments. The main goals are to find a safe dose and…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for blood cancer patients: experimental drug enters major trial
Disease control Not yet recruitingThis study is testing a new drug, BL-M11D1, in combination with two different sets of standard chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). The main goals are to find a safe and effective dose and to see how well the combinations work to contro…
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC